Tongxinluo and Functional Outcomes Among Patients With Acute Ischemic Stroke: A Randomized Clinical Trial.

ABSTRACT:

Importance

Previous studies revealed limited effectiveness of neuroprotective agents in treating acute ischemic stroke (AIS). Tongxinluo, developed from traditional Chinese medicines, has been recognized as a novel neuroprotective agent with anti-inflammatory properties that stabilize vulnerable plaques in animal models and patients with myocardial infarction.

Objective

To assess the efficacy and safety of Tongxinluo in patients with acute ischemic stroke (AIS).

Design, setting, and participants

This multicenter, open-label, double-blind, randomized clinical trial included 2007 patients with AIS and a National Institutes of Health Stroke Scale score between 4 and 22 at admission. The trial was conducted at 50 hospitals in China from March 1, 2014, to October 31, 2016.

SUBMITTER: Dong Y 

PROVIDER: S-EPMC11428006 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature